Skip to main content

LCD L33579: Transesophageal Echocardiography (TEE)

LCD L33579, Transesophageal Echocardiography (TEE), is the Local Coverage Determination that Wellpoint Federal applies to claims from 10 states (CT, IL, MA, ME, MN, NH, NY, RI and others), effective 2026-04-01 and first in force 2015-10-01. The policy text runs 1,894 words, and its billing and coding article A52868 lists 776 ICD-10-CM codes that support medical necessity for 17 procedure codes. 2 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 776 covered ICD-10-CM codes: 273 more codes than L35016 (Novitas Solutions, Inc., 503 codes, revised 2019-10-17) and 307 more codes than L34337 (CGS Administrators, LLC, 469 codes, revised 2026-09-03).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wellpoint Federal
States and territories
10
CT IL MA ME MN NH NY RI VT WI
Revision effective
2026-04-01
Original effective
2015-10-01
Policy text
1,894 words
Covered ICD-10 codes (articles)
776

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L33579
ContractContractorTypeStates
06101Wellpoint FederalMAC - Part AIL
06201Wellpoint FederalMAC - Part AMN
06301Wellpoint FederalMAC - Part AWI
06102Wellpoint FederalMAC - Part BIL
06202Wellpoint FederalMAC - Part BMN
06302Wellpoint FederalMAC - Part BWI
13101Wellpoint FederalA and B and HHH MACCT
13201Wellpoint FederalA and B and HHH MACNY
13102Wellpoint FederalA and B and HHH MACCT
13202Wellpoint FederalA and B and HHH MACNY
13282Wellpoint FederalA and B and HHH MACNY
13292Wellpoint FederalA and B and HHH MACNY
14411Wellpoint FederalA and B and HHH MACRI
14211Wellpoint FederalA and B and HHH MACMA
14311Wellpoint FederalA and B and HHH MACNH
14511Wellpoint FederalA and B and HHH MACVT
14111Wellpoint FederalA and B and HHH MACME
14112Wellpoint FederalA and B and HHH MACME
14212Wellpoint FederalA and B and HHH MACMA
14312Wellpoint FederalA and B and HHH MACNH
14512Wellpoint FederalA and B and HHH MACVT
14412Wellpoint FederalA and B and HHH MACRI

Billing and coding article A52868: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A52868 (Billing and Coding: Transesophageal Echocardiography (TEE)) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A52868: Billing and Coding: Transesophageal Echocardiography (TEE) (Billing and Coding, effective 2026-10-01)

Covered ICD-10-CM codes
776
3 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
17
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A52868
ICD-10-CMDescription (FY2027)
A02.1Salmonella sepsis
A18.84Tuberculosis of heart
A22.7Anthrax sepsis
A26.7Erysipelothrix sepsis
A32.7Listerial sepsis
A40.0Sepsis due to streptococcus, group A
A40.1Sepsis due to streptococcus, group B
A40.3Sepsis due to Streptococcus pneumoniae
A40.8Other streptococcal sepsis
A40.9Streptococcal sepsis, unspecified
A41.01Sepsis due to Methicillin susceptible Staphylococcus aureus
A41.02Sepsis due to Methicillin resistant Staphylococcus aureus
A41.1Sepsis due to other specified staphylococcus
A41.2Sepsis due to unspecified staphylococcus
A41.3Sepsis due to Hemophilus influenzae
A41.4Sepsis due to anaerobes
A41.50Gram-negative sepsis, unspecified
A41.51Sepsis due to Escherichia coli [E. coli]
A41.52Sepsis due to Pseudomonas
A41.53Sepsis due to Serratia
A41.54Sepsis due to Acinetobacter baumannii
A41.59Other Gram-negative sepsis
A41.81Sepsis due to Enterococcus
A41.89Other specified sepsis

Procedure codes: 76376, 76377, 93312, 93313, 93314, 93315, 93316, 93317, 93318, 93319, 93320, 93321, 93325, 93355, C8925 (Transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, real time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report), C8926 (Transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report), C8927 (Transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, for monitoring purposes, including probe placement, real time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis).

Coverage indications, limitations and medical necessity

Abstract:

Transesophageal echocardiography (TEE) is ultrasonic examination of the heart performed by placing the transducer in the esophagus which allows different views of the heart than transthoracic echocardiography (TTE). TEE is particularly useful for posterior structures, such as the pulmonary veins, left atrium, and mitral valve and provides better visualization of the aortic root, valve and the ascending and descending aorta and arch.

TEE is frequently performed because TTE was not technically adequate. In addition, there are a number of medical conditions for which TEE is preferred over transthoracic echocardiography (see indications below). TEE is considered medically necessary when there is a reasonable expectation that it will both provide information not available with TTE or other less invasive forms of imaging and significantly contribute to management decisions regarding treatment of the patient.

In order to qualify as a valid echocardiographic service, the study must be done for an accepted clinical indication by a properly trained examiner and must include a permanent record of the findings, data sufficient to support the conclusions and an appropriate interpretation and written report.

This policy addresses the medically necessary and appropriate application of TEE. Transthoracic echocardiography (TTE) is the subject of a separate policy statement.

Indications:

Mitral valve disease:

TEE is indicated for the following:

• When needed to assess the etiology of mitral regurgitation

• When needed to assist in the decision making: mitral valve repair vs. replacement

Endocarditis:

TEE is indicated for the following:

• When the suspicion of endocarditis is high (persistent febrile state, negative cultures, preexistent valvular pathology) and TTE does not document endocarditis. TEE may define small vegetative masses and more completely delineate local complications (e.g., ring abscesses, aneurysm, fistulae).

• Re-evaluation in complex endocarditis;

• Evaluation of bacteremia without known source;

• Evaluation of suspected or actual prosthetic valve endocarditis otherwise obscured because of reverberations and other image artifacts related to mechanical or other non-native valves during TTE.

Valvular Prostheses (mechanical and bioprostheses): TEE is indicated in the evaluation of suspected prosthetic valve dysfunction when therapeutic decisions are critical and TTE is inconclusive and/or when the left atrium must be well-visualized. TEE is not routinely indicated in all patients with prosthetic valves.

Suspected Cardiac Thrombi and Emboli:

TEE is indicated for the following:

• Evaluation of the left atrium and atrial appendage for clot, when clot is not visualized on TTE;

• Evaluation for an ASD, patent foramen ovale or atrial septal aneurysm with clot; and

• Evaluation of the mitral valve in patients with a history of emboli.

Cardiac/Pericardial Masses and Other Pericardial Disease:

TTE and TEE have comparable sensitivity in the assessment of right heart masses. Therefore, TEE is indicated for the following:

• Visualization of left atrial masses when needed to provide therapeutic direction (cystic vs. solid, attachment, infiltration);

• When cardiac mass lesions (including tumors on cardiac valves) are suspect and cannot be visualized on TTE, and TEE is needed for development of a management strategy;

• To assess pericardial effusion when surface studies do not provide adequate information. "The risk of pericardiocentesis may be reduced by the use of echocardiographic guidance and monitoring of needle aspiration, particularly for loculated or small effusions." (ACC/AHA/ASE 2003 Guideline Update, pg. 39).

Aortic Pathological Conditions and Diseases of the Great Vessels:

• TEE may be indicated when adequate visualization of the aortic root is not sufficient with TTE.

• TEE may be indicated for identification of aortic dissection, aortic ulceration, atherosclerotic plaque, and mural thrombotic material.

• TEE has a particularly high degree of sensitivity and specificity for aortic dissection. TEE is the technique that is indicated in examination of the entire aorta, especially in emergency situations.

• Because descending thoracic aortic aneurysms are difficult to visualize using TTE, TEE is recommended for this condition.

• Visualization of the superior vena cava and diagnosing various congenital and acquired abnormalities, such as vena caval thrombosis;

• Visualization of the proximal inferior vena cava, vena caval dilation and detection of thrombosis or extension of tumors from the inferior vena cava to the right-heart chambers;

• Visualization of all four pulmonary veins;

• Evaluation of the heart and great vessels following blunt trauma to the chest (e.g., rupture or transsection of the aorta, acute dissection, hematoma, etc.)

• When needed to assist in the decision making prior to aortic valve operative intervention.

Congenital Heart Disease:

TEE is indicated for the following:

• Patients with congenital heart disease postoperatively where fibrosis, echo opaque patches and prostheses, inadequate penetration, and acoustical shadowing can result in incomplete TTE data;

• Patients in which TTE is technically inadequate or anatomic definition is incomplete;

• Patients in whom a more precise definition of atrial, outflow tract and proximal pulmonary vascular anomalies by TEE can be critical to management strategies;

• To assess complications of congenital heart surgery, visualization of shunt flow across atrial-septal defects, guidance of clamshell device to close atrial-septal defects, diagnosis of cor triatriatum, and detection of pulmonary valve abnormalities.

Critically Ill Patients:

TEE is indicated for the following:

• Management of the critically ill patient when TTE is otherwise contraindicated (e.g., chest or other major trauma) or inadequate (e.g., patient on a ventilator or with COPD, or in postoperative patients who are unable to be positioned for TTE);

• Patients with persistent hypoxemia having suspected right-to-left shunt;

• Patients with complications of myocardial infarction (ruptured septum, papillary muscle, or free wall);

• Hemodynamically unstable patients in whom TTE images are suboptimal;

• Evaluation of brain-dead patients being considered as cardiac donors;

• Persistent unexplained fever when endocarditis or myocardial abscess is suspected and TTE is non-diagnostic.

Interventional and Surgical TEE:

TEE is indicated for the following:

• Guidance during percutaneous cardiac interventions such as during the creation of shunts, placement of septation devices, valvuloplasty procedures, endomyocardial biopsy, electrophysiologic studies/procedures, placement of septal or atrial appendage occluders or during percutaneous valve replacement;

• Intraoperative evaluation to assess prosthetic or repaired/reconstructed valve function, or the integrity/function of complex congenital heart repairs;

• Intraoperative evaluation to assess the integrity of the cardiopulmonary circulation in patients during lung or heart-lung transplants; and

• Intraoperative assessment for presence and/or severity of outflow tract obstruction or presence/repair of an intracardiac shunt;

• Intraoperative assessment of wall motion abnormalities in the case of acute deterioration in the patient's status, once the chest has been closed;

• Only TEE done for specific diagnostic purposes may be separately payable during intraoperative use (TEE used for monitoring purposes is not separately payable). The results of the test must be used in making management decisions on the patient's intraoperative treatment. A covered service must include a complete interpretation/report by the performing physician, and must be available if requested.

Doppler Color Flow Velocity Mapping:

• Spectral Doppler echocardiography and Doppler color flow-velocity mapping may be necessary in addition to an echocardiogram when the examination could contribute significant information to the patient's condition or treatment plan. Typically, Doppler is indicated in the evaluation of some heart murmurs, valvular problems, shunts, suspected congenital heart disease, complications of myocardial infarction, or cardiomyopathy. Doppler should be medically necessary for the evaluation and management of the patient.

• "Color/spectral Doppler may not be useful or appropriate in certain relatively small and well-defined patient populations when there is a recent comprehensive examination and the test is being ordered for re-evaluation of a limited problem." (ASE comment).

• The use of the Doppler is inherent in the ultrasonic cardiac evaluation. However, if the test reports fail to document the use of this technique to assess these structures and function (e.g., measurement of valvular insufficiency or stenosis, myocardial diastolic function, etc. as described by the ASE), or if the medical records fail to document that the examination was "clinically necessary" (e.g., follow-up of pericardial effusion size) then the Doppler portion of the test may be considered medically unnecessary and denied.

3-Dimensional Echocardiography

When billed with TEE, it is indicated for:

• The pre-operative planning of valve repair for multiple etiologies of mitral regurgitation;

• Assessment of mitral stenosis and in the accurate calculation of mitral valve area;

• Pre-operative planning for diagnosis and treatment of atrial septal defects;

• Pre-operative and intraoperative planning for interventional cardiac procedures (e.g., transcatheter placement of occluders for atrial septal defects or patent foramen ovales, or paravalvular dehiscence or leaks;

• Intraoperative mapping for atrial ablation procedures.

• The evaluation of tricuspid valve disease.

While three-dimensional echocardiography may provide improved calculation of volume when compared to 2D echocardiography, its value in affecting clinical outcomes is not yet proven and it is therefore not medically necessary.

TEE is indicated for cardioversion in patients:

• Requiring urgent (not emergent) cardioversion for whom extended pre-cardioversion anticoagulation is not desirable;

• Who have had prior cardioembolic events thought to be related to intra-atrial thrombus;

• For whom anticoagulation is contraindicated and for whom a decision about cardioversion will be influenced by TEE results;

• For whom intra-atrial thrombus has been demonstrated in previous TEE. (ACC/AHA/ASE 2003 Guideline Update, pgs. 49-50)

Limitations:

Screening examinations to identify structural cardiac abnormalities in the absence of established diagnoses, signs or symptoms, are not considered reasonable and necessary.

TEE does not provide incremental information over that obtained by TTE in the serial assessment and management of pericardial pathology. Therefore, it will not be covered, unless there are loculated posterior effusions or adequate visualization of the pericardium is not possible by TTE.

In general, TTE provides accurate and serial noninvasive assessment of global and regional left ventricular function. Unless TTE is technically inadequate and clinical data is insufficient for a management decision, TEE will not be covered. Transthoracic echocardiographic assessment of left ventricular function is considered preferable to TEE in all other circumstances.

Intraoperative TEE is reimbursable to a qualified cardiologist, cardiac surgeon, anesthesiologist or other qualified physician but only when performed as a significant, separately identifiable diagnostic test, with a formal written report, and not for monitoring purposes.

In aortic root dilation in Marfan Syndrome or other connective tissue syndromes, the ACC AHA/ASE 2003 Guideline Update recommends TTE over TEE as the first choice for examination. "TEE should only be used if the examination is incomplete or additional information is needed." (pg. 42.)

In most patients with valvular prostheses TTE provides diagnostic functional information and noninvasive serial follow-up. However, in some patients, acoustical shadowing can decrease data acquisition. If TTE provides adequate information for diagnosis and management, then TEE is not covered. The medical record should document any need for additional information.

In general, TTE can reliably diagnose or exclude evidence of potentially embolic material located in a ventricle. The TEE may complement TTE, particularly to assess for left atrial thrombus and patent foramen ovale or atrial septal aneurysm. The additional information that can be provided by TEE should be reasonably anticipated to be of therapeutic relevance before the patient is subjected to TEE, otherwise the TEE is not covered.

Training Requirements:

Medicare expects a satisfactory level of competence from providers who submit claims for services rendered for these services to be considered medically necessary. Tests performed by providers not meeting these levels of competence will be denied.

The acceptable levels of competence are outlined as follows:

a. For the technical portion, an acceptable level of competence is fulfilled when the image acquisition is obtained under any one of the following conditions:

• The service is performed by a physician; or

The policy text continues in the CMS record.

Summary of evidence (opening)

The National CCI Manual, version 13.3, Chapter II: CCI editing for anesthesia services; accessible at http://www.cms.hhs.gov/NationalCorrectCodInitEd/

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2026-04-01
Last reviewed by the contractor
2024-08-19
MCD version
39
Derived from
L27381

The contractor lists one National Coverage Determination as related: NCD 220.5 Ultrasound Diagnostic Procedures. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A59913 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L33579 cover?

Transesophageal echocardiography (TEE) is ultrasonic examination of the heart performed by placing the transducer in the esophagus which allows different views of the heart than transthoracic echocardiography (TTE). TEE is particularly useful for posterior structures, such as the pulmonary veins, left atrium, and mitral valve and provides better visualization of the aortic root, valve and the ascending… The full 1,894-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L33579 apply to?

Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; 2 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L33579?

The companion billing and coding article A52868 lists 776 ICD-10-CM codes in 3 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L33579?

A denial under LCD L33579 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A52868's 776 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.